The short version
- Clearing senescent cells delayed ageing-associated disorders in mice in 2011, and intermittent oral senolytics increased post-treatment survival by 36% in aged mice in 2018.
- The first human senolytic study treated 14 patients with idiopathic pulmonary fibrosis open-label with no control group, and its primary endpoints were retention and completion rates rather than efficacy.
- A nine-person open-label study confirmed that dasatinib plus quercetin reduces senescent cell burden in human adipose tissue and skin, which is mechanistic proof rather than clinical benefit.
- The first randomised controlled trial of senolytics, in 60 postmenopausal women, missed its primary bone resorption endpoint at 20 weeks.
- Dasatinib is a prescription tyrosine kinase inhibitor used to treat leukaemia, so no over-the-counter product contains the combination that every one of these studies actually tested.
Every so often the longevity field produces an idea good enough that you understand why people get carried away. Senolytics is that idea. Cells that stop dividing but refuse to die accumulate in ageing tissue and secrete inflammatory signals. Remove them and, in principle, you remove a driver of decline rather than treating a symptom.
The biology is real. What is being sold on the back of it is not the thing that was tested.
The animal work, which is genuinely strong
In 2011, Baker and colleagues reported in Nature that clearing p16Ink4a-positive senescent cells delayed the onset of ageing-associated disorders in mice — a proof of principle that senescent cells are causal rather than incidental.
Seven years later, Xu and colleagues went further. Transplanting relatively small numbers of senescent cells into young mice caused persistent physical dysfunction and spread senescence to host tissues. Fewer cells were needed to do it in older recipients, and it reduced their survival. Then the reverse: intermittent oral senolytics in both transplanted young mice and naturally aged mice alleviated the physical dysfunction and increased post-treatment survival by 36%, reducing the mortality hazard to 65%.
That is about as clean as preclinical work gets. Cause established in both directions, in mammals, with a functional and a survival endpoint.
Now the human trials, in full
There are not many, and they are small.
The first-in-human study, in 2019, gave dasatinib plus quercetin to fourteen patients with idiopathic pulmonary fibrosis over three weeks. It was open-label — everybody knew what they were getting, and there was no control group. Its primary endpoints were retention and completion rates, because the point was to establish whether such a trial could be run at all. Physical function measures including six-minute walk distance and gait speed improved significantly; pulmonary function, clinical chemistry, frailty index and reported health were unchanged. One serious adverse event was reported.
The second, later the same year, enrolled nine people with diabetic kidney disease for three days of treatment, also open-label. It did the thing nobody had shown before: adipose tissue senescent cell burden actually fell, along with skin p16 and p21 positive cells and circulating inflammatory factors. That is important mechanistic confirmation that the drugs do in humans what they do in mice.
Neither trial had a placebo group. Both were explicitly labelled pilots by their authors.
The first proper randomised trial, and its result
In 2024, Farr and colleagues published a phase 2 randomised controlled trial of intermittent dasatinib plus quercetin in 60 postmenopausal women, looking at bone metabolism.
The primary endpoint — change in the bone resorption marker CTx at 20 weeks — did not differ between groups. A bone formation marker rose significantly at 2 and 4 weeks but was no different from control by 20 weeks. No serious adverse events. In exploratory analysis, women in the highest tertile of senescent cell burden did show a skeletal response, which is a genuinely interesting hypothesis for the next trial and is not a result you can act on today.
So the scoreboard in humans reads: mechanism confirmed, function improved in an uncontrolled pilot of fourteen, primary endpoint missed in the first randomised trial. Nobody has measured lifespan, healthspan or physical function in a placebo-controlled senolytic trial in healthy people, because that trial has not been run.
The part that should stop you buying anything
The senolytic combination in every one of those studies is dasatinib plus quercetin. Dasatinib is a prescription tyrosine kinase inhibitor used to treat leukaemia. It is not a supplement, it is not available over the counter, and it has the side effect profile of a cancer drug.
Quercetin, the half you can buy, has never been shown to work alone as a senolytic in a human trial. A quercetin capsule marketed with the word senolytic on it is borrowing the credibility of studies that used a chemotherapy agent alongside it, at 1,000 to 1,250mg of quercetin per day in short intermittent bursts — a protocol nothing on a shelf is telling you to follow.
Fisetin gets marketed the same way on the same borrowed evidence. The registered human trials are underway; they have not reported the outcomes people are citing.
Why we bothered writing this
Because this is the exact shape of the mistake we want our customers to recognise, and it repeats. Spermidine has the mechanism and a null trial. Taurine had the mouse lifespan result and a human premise that failed replication. Senolytics have the best preclinical case of the three and the widest gap between what was tested and what is sold.
If you want the version of this with a human hazard ratio attached, it is still VO2 max, and it is still free.
What we would actually tell you
Do not buy a senolytic. Not from us — we do not sell one — and not from anyone, because the product available to you is not the intervention that was studied.
Keep an eye on the field, though. This is the one entry in the longevity aisle where we would genuinely expect a positive randomised trial within the decade. Being interested in an idea and buying a capsule labelled after it are different acts, and the gap between them is where most money in this category disappears.
Good questions
Can I buy senolytics as a supplement?
No, not the ones that were studied. Every human senolytic trial to date used dasatinib plus quercetin, and dasatinib is a prescription leukaemia drug. Quercetin on its own has never been shown to work as a senolytic in a human trial. A capsule marketed with the word senolytic on it is borrowing credibility from studies it had no part in.
Does quercetin clear senescent cells?
Not on the evidence available for quercetin alone in humans. It has only ever been tested in combination with dasatinib, at 1,000 to 1,250mg per day in short intermittent bursts, and the effect cannot be attributed to one component of a two-drug combination. If your bottle implies otherwise, the implication is unsupported.
Has any senolytic trial actually worked in people?
Mechanistically yes, clinically not yet. A nine-person study confirmed the drugs reduce senescent cell burden in human tissue. A fourteen-person open-label pilot showed improved walking and gait speed with no control group. The first randomised controlled trial, in 60 postmenopausal women, missed its primary endpoint.
What about fisetin?
Fisetin is being tested and has not reported the outcomes it is marketed on. Registered human trials are underway. Until one publishes a controlled result, buying fisetin as a senolytic means paying for a hypothesis. The animal data is interesting; that is not the same as a reason to spend money this month.
Is it worth waiting for senolytics?
Watching the field costs nothing and we think it is worth doing. This is the entry in the longevity aisle where we would most expect a positive randomised trial within the decade. In the meantime the interventions with proven human mortality data are the unglamorous ones, and none of them is sold in a bottle.
Are senescent cells the cause of aging?
They are one causal contributor, which the mouse work established convincingly in both directions. Transplanting senescent cells into young mice caused lasting physical dysfunction; removing them in aged mice improved function and survival. Calling them the cause of ageing overstates it, and treating a single mechanism as the whole story is how this field keeps getting ahead of itself.
Sources
- Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature, 2011. View study
- Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med, 2018. View study
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 2019. View study
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine, 2019. View study
- Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med, 2024. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
